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Abstract
Background: Combined treatment with cisplatin and gemcitabine (CisGem) is the standard of care for patients
with advanced biliary tract cancer (ABC). Selumetinib (AZD6244, ARRY-142886) potently and selectively inhibits
MEK1/2, an intracellular kinase and has shown activity in ABC. The objective of the ABC-04 trial was to establish
the recommended dose of selumetinib in combination with CisGem in patients with ABC.
Methods: Eligible patients were≥ 18 years, had histologically or cytologically-confirmed unresectable recurrent or
metastatic biliary tract, gallbladder or ampullary carcinoma, WHO performance status 0–2, and adequate major organ
function. Patients may have had prior surgery, radiotherapy or adjuvant chemotherapy, but no prior CisGem and no
prior chemotherapy for locally advanced or metastatic disease. Patients received cisplatin 25 mg/m2 plus gemcitabine
1000 mg/m2 intravenously on days 1 and 8 of a 21-day cycle. Selumetinib capsules were taken daily. Patients received
up to 8 cycles of CisGem and could receive selumetinib until disease progression. A dose de-escalation scheme was
used to determine the recommended dose of selumetinib. The first dose level was 75 mg bd. Patients were recruited
in cohorts of 3 and assessed for dose limiting toxicity (DLT) during the first cycle of treatment.
Results: Thirteen patients were recruited, of whom 12 were evaluable for DLT (1 did not start treatment). All evaluable
patients received the starting dose of selumetinib 75 mg bd and one patient experienced a DLT (cardiac chest pain).
The median number of days selumetinib was taken (adjusted for the number of days of dose interruptions) was 171.5
(IQR: 75.5 to 344). Two patients remained on treatment at 14 and 19 months post registration. There were 3 temporary
and 1 permanent interruptions of selumetinib in cycle 1. Eight patients were evaluable for objective response (RECIST
v1.1): 3 had a partial response and 5 stable disease. The median PFS was 6.4 months (IQR 5.2 to 13.7). Toxicities related
to selumetinib were mostly related to oedema and rash, grade 1–2 and manageable. Pharmacokinetic analysis showed
that the AUC(0-t), AUC(0-∞) and Cmax of selumetinib increased by 12, 11 and 30 % respectively when it was
administered with CisGem, while Cmax for the N-desmethyl metabolite of selumetinib decreased by 40 %. There was
no evidence that the time of Cmax for selumetinib or N-desmethyl metabolite of selumetinib were different when
selumetinib was administered alone or with CisGem.
Conclusion: The recommended dose of selumetinib when combined with CisGem was 75 mg bd. Translational
studies are underway to identify biomarkers that may predict outcome (ClinicalTrials.gov identifier: NCT01242605 July
6th 2010).
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Background
Biliary tract cancer is an uncommon cancer in developed
countries with approximately 1200 new cases in the UK
and 9000 new cases in the United States per year. The
incidence is increasing, perhaps related to gall stone dis-
ease. Most patients have advanced disease at presentation,
or relapse after surgery for localised disease. The National
Cancer Research Institute (UK) ABC-02 study demon-
strated the combination of cisplatin and gemcitabine to be
an effective first line treatment and this combination has
become the international standard of care [1].
Selumetinib (AZD6244, ARRY-142886) is a potent and
selective inhibitor of MEK [MAPK (mitogen-activated
protein kinase)-ERK (extracellular-signal-regulated kinase)
kinase]. Selumetinib inhibits phosphorylation of ERK2 by
MEK and decreased levels of phosporylated ERK (pERK)
post treatment have been shown to correlate with efficacy
[2, 3]. Mutations in the genes of downstream signaling
molecules such as KRAS and BRAF have been found to
be associated with resistance to cetuximab but these ef-
fects are, to a certain extent, tissue and context dependent
[4, 5].
In the clinic, selumetinib 75 mg twice daily (bd) has
been tolerated in combination with docetaxel or dacarba-
zine in phase II studies [6, 7]. Bekaii-Saab and colleagues
[8] conducted a phase II trial of selumetinib monotherapy
at 100 mg bd in 29 patients with ABC, 39 % of whom had
received prior chemotherapy. An older formulation of
selumetinib was used in Bekaii-Saab’s trial and the expos-
ure from the 100 mg dose would have been similar to the
75 mg dose of the new formulation used in ABC-04. The
response rate was 12 % which is comparable with single
agent gemcitabine in this setting. Decreased levels of
pERK were associated with selumetenib as well as im-
proved progression free survival and putative effects on
muscle bulk were also observed [9].
In summary, selumetinib has shown promise in ABC as a
single agent and has been safely combined with chemother-
apy. These data suggested that selumetinib may be effective
in combination with CisGem for patients with ABC. We
performed a phase Ib study of the CisGem+ selumetinib
combination to determine the recommended dose of selu-
metinib for subsequent efficacy-based studies. Secondary
objectives were to investigate pharmacokinetic (PK) interac-
tions between selumetinib and gemcitabine, to determine
the objective tumour response rate (ORR) by CT or MRI,
and to determine time to progression or death from any
cause (PFS and OS).
Methods
Trial design and treatment
ABC-04 was a phase Ib, multicentre, open-label trial
which used a dose de-escalation strategy to determine
the recommended dose of selumetinib in combination
with CisGem (ClinicalTrials.gov identifier: NCT01242605).
A dose de-escalation strategy was chosen since previous
trials had shown that 75 mg bd selumetinib could be given
safely with chemotherapy; namely, docetaxel [6] and dacar-
bazine [7]. Four dose levels were included in the protocol
for potential evaluation; 75 mg bd, 50 mg bd, 75 mg once
daily (od) and 50 mg od. The first dose level evaluated was
75 mg bd. Patients were recruited in cohorts of three. The
number of patients experiencing a DLT during the first
cycle of treatment in each cohort was used to decide the
dose level at which to recruit the next cohort. If no patients
experienced a DLT, then that dose level was the recom-
mended dose. If one patient experienced a DLT, the cohort
was to be expanded to six patients. If > 2 patients experi-
enced DLT, then subsequent patients were to be entered
into the next lower dose level. A minimum of 12 patients
were to be treated at the recommended dose to further
establish safety.
Chemotherapy consisted of cisplatin 25 mg/m2 plus gem-
citabine 1000 mg/m2 administered intravenously (IV) on
days 1 and 8 of a 21-day cycle for up to 8 cycles, as previ-
ously described [1]. Pre-chemotherapy hydration and anti-
emetic regimens were as per each site’s policy. Selumetinib
was taken orally each day throughout chemotherapy. Three
consecutive days of selumetinib were administered prior to
the first cycle of chemotherapy in order to obtain PK data
for selumetinib alone. Patients could continue with selume-
tinib after completion of chemotherapy until disease pro-
gression if it was deemed to be in the best interests of the
patient.
The trial was reviewed and approved by the South
Central-Berkshire Research Ethics Committee and the
Medicines and Healthcare Products Regulatory Authority.
Global National Health Service (NHS) permission was
granted by the Central and East London Comprehensive
Local Research Network (CLRN), and the trial was ap-
proved by the Research and Development department of
each participating NHS Trust. The trial was performed in
accordance with the principles of International Conference
on Harmonisation Good Clinical Practice Guidelines. It
was coordinated by the Cancer Research UK and University
College London Cancer Trials Centre and sponsored by
University College London. The views expressed are those
of the authors and not necessarily those of the NHS, the
NIHR or the Department of Health.
Patients
Patients were eligible if they had a histopathological or
cytological diagnosis of non-resectable, recurrent or
metastatic biliary tract (intra- or extra-hepatic), gallblad-
der or ampullary carcinoma for which no prior systemic
chemotherapy had been given. Patients were required to
have World Health Organisation (WHO) performance sta-
tus ≤ 2, be aged ≥ 18, have an estimated life expectancy >
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3 months, and have adequate biliary drainage and major
organ function. Patients had to be able to swallow selumeti-
nib capsules and be capable of giving written informed
consent. Patients were not eligible if they had had any prior
exposure to MEK, RAS, or RAF inhibitors, had not fully
recovered from previous surgery, had had a prior malig-
nancy (except curatively treated in-situ carcinoma of the
cervix, non-metastatic basal and/or squamous cell carcin-
omas of the skin, or any early stage (stage I) malignancy
adequately resected for cure greater than 5 years previ-
ously), had evidence of a severe or uncontrolled systemic
disease, if the patient was pregnant or breast-feeding, or
had any of the following cardiac conditions: uncontrolled
hypertension (blood pressure ≥150/95 despite optimal ther-
apy), heart failure (New York Heart Association Class II or
above), prior or current cardiomyopathy, baseline left ven-
tricular ejection fraction ≤ 50 %, atrial fibrillation with heart
rate >100 beats per minute, unstable ischaemic heart dis-
ease (myocardial infarction within 6 months prior to start-
ing treatment, or angina requiring use of nitrates more
than once weekly).
All patients gave written informed consent prior to any
trial-specific interventions.
Assessments
Patients were assessed prior to starting treatment and
at regular intervals throughout treatment. Physical ex-
aminations, including vital signs and assessment of
adverse events (AEs) were carried out prior to regis-
tration, on days 1 and 8 of each cycle of chemotherapy
and monthly for patients who continued on selumeti-
nib alone. All AEs occurring between the date of sign-
ing consent and 30 days after the last dose of any trial
treatment were recorded. AEs were graded according
to CTCAE v 4.03. Blood biochemistry and a full blood
count with differential were carried out at the same
time points as the physical examinations. Patients who
had a calculated creatinine clearance of < 45 mL/min
prior to treatment were required to have an isotopic
glomerular filtration rate (GFR) test to confirm GFR >
45 mL/min. In addition, prior to registration, an elec-
trocardiogram and echocardiogram, and an ophthal-
mological examination were required. Disease status
was assessed by computed tomography (CT) scan,
with or without a liver magnetic resonance (MR) scan,
prior to registration, after cycles 4 and 8 and then
subsequently every 12 weeks until disease progression.
Patients with measurable disease at baseline were
assessed for objective response according to RECIST
v1.1 [10]. For patients with non-measurable disease,
objective response was not assessed and progressive
disease was documented by the appearance of new
lesions or by symptomatic deterioration.
Dose limiting toxicity
Patients were assessed for DLT during the first cycle of
treatment. Patients experiencing any of the following
drug-related adverse events were considered to have expe-
rienced a DLT: Any grade 3 or 4 AE or laboratory abnor-
mality that was deemed clinically significant by the
investigator; infusion-related reactions were considered a
DLT based on the study team’s medical review of the
event; grade 3 fatigue that persisted for > 7 days, or grade
4 fatigue; grade 3 or 4 nausea, diarrhoea, or vomiting des-
pite maximum supportive care; magnesium <0.4 mmol/L;
grade 3 rash/desquamation for > 7 days; grade 3 or 4
neutropenia with fever ≥ 38.5 °C lasting 3 days or more;
grade 4 neutropenia or thrombocytopenia > 7 days; ALT
or AST > 10 x ULN; patient was unable to tolerate a total
of at least one three week dosing course due to adverse
event(s); any AE resulting in a more than 14 day treatment
delay for any agent. To be evaluable for evaluation of the
recommended dose, the patient must have completed
21 days (3 weeks or 1 cycle) of therapy must and received
80 % of expected dose of all drugs, or the patient must
have experienced a DLT during cycle 1. Patients who did
not meet these criteria were replaced.
Pharmacokinetics
Blood samples were collected from all patients entering the
study for the determination of plasma drug and metabolite
concentrations for selumetinib. Cisplatin pharmacokinetics
were not analysed as an interaction with selumetinib was
unlikely since the metabolic pathways are different. Samples
were taken for analysis of the effect of selumetinib on
gemcitabine PK. However, the gemcitabine sample collec-
tion was incomplete therefore only selumetinib PK are
presented.
Blood samples for selumetinib PK analysis were col-
lected at the following time points: before the start of trial
treatment; on the third day of selumetinib dosing (selume-
tinib alone) just before the morning dose and after the
morning dose at 15 min, 30 min, 1 h, 1.5 h, 2 h, 4 h, 8 h,
10 h (before the evening dose of selumetinib for bd
dosing), and 24 h (before the morning dose of selumetinib
and start of chemotherapy); On cycle 1 day 8 (selumetinib
+ CisGem) before the morning dose of selumetinib and
before chemotherapy and after the morning dose of
selumetinib at 15 min, 30 min, 1 h (at end of cisplatin
infusion), 1.5 h, 2 h (at end of gemcitabine infusion), 4 h,
8 h, 10 h (before the evening dose of selumetinib for bd
dosing), and 24 h (before the morning dose of
selumetinib).
Where data allowed, the following PK parameters were
determined following administration selumetinib alone
and following administration of selumetinib and CisGem
together. For selumetinib alone, maximum observed
concentration (Cmax), time to Cmax (tmax), area under the
Bridgewater et al. BMC Cancer  (2016) 16:153 Page 3 of 9
curve (AUC)(0-12) and apparent oral clearance (CL/F,
Apparent oral clearance = (dose*F)/AUC where F = abso-
lute bioavailability of the drug), and when given in com-
bination, Cmax ratio, AUC(0-12) ratio. For N-desmethyl
selumetinib when selumetinib was given alone, Cmax,
tmax, AUC(0-12), AUC(0-t), CL/F, metabolite:parent ratio
for Cmax and AUC(0-12), and given in combination with
CisGem: Cmax ratio, AUC ratio.
Other statistical analyses
Tumour responses were assessed according to RECIST
version 1.1. The best response across all time points has
been reported. For PFS and OS, the time to progression
or death was measured from the date of registration.
PFS and OS were estimated for the population by the
Kaplan-Meier method.
All safety data was summarized by frequency and per-
centage and presented for each dose as appropriate.
Worst grade per patient has been reported.
Results
Recruitment information
Thirteen patients were recruited from 3 centres in the
United Kingdom between February 2012 and January
2013 of whom 12 were evaluable for DLT (Fig. 1). The
median follow-up time was 20.4 months using censored
deaths method. The data cut off was 28th April 2014
(Fig. 2).
Baseline characteristics
Patient demographics are given in Table 1. The median
age was 65 years (range: 45–81 years); 9 patients (69 %)
had bile duct as the primary site of disease, 3 (23 %) had
gall bladder cancer and 1 (8 %) had ampullary cancer.
The advanced stage of patients’ disease was evident by
high T stage (T3-4) in 70 %, LN positive disease in 46 %
and the presence of metastases in 77 % of patients. A
total of 8 patients (62 %) had previous surgery and 7
(54 %) had biliary stent insertions.
Compliance with CisGem chemotherapy
One patient withdrew from the trial before starting treat-
ment due to ill health (gallbladder perforated into the liver
causing a collection requiring drainage via a cholecystost-
omy). Five patients (42 %) completed 8 cycles of CisGem.
Of the 7 who did not complete 8 cycles of CisGem, 3
stopped early due to disease progression, 1 patient due do
symptomatic deterioration and 3 patients due to unaccept-
able adverse events (1 had grade 3 angina/chest pain
cardiac (1 cycle of chemotherapy and selumetinib), 1 had
grade 3 duodenal haemorrhage (7 cycles of chemotherapy
and selumetinib), and 1 had multiple low grade toxicities &
recurrent urinary tract infections (4 cycles of chemotherapy
and selumetinib)).
Fig. 1 Consort diagram for the ABC-04 study
Fig. 2 Kaplan Meier curve of progression free survival
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Compliance with selumetinib
The median length of time selumetinib was taken was
171.5 days (IQR: 75.5 to 344). Four selumetinib dosing
suspensions occurred during cycle 1 of chemotherapy.
One patient stopped selumetinib permanently during
cycle 1 due to grade 3 cardiac chest pain, and this was
considered to be a DLT. Three patients each had one
temporary suspension of selumetinib during cycle 1 all
of which were less than 14 days (blurred vision, dys-
pnoea and chest pain, and vomiting and depressive
symptoms). At the time of the final analysis, ten patients
had stopped selumetinib permanently: 4 (40 %) due to
adverse events (see Additional file 1: Table S2) and 5
(50 %) due to disease progression or symptomatic deteri-
oration. All 12 patients had at least one temporary sus-
pension of selumetinib at some point during their time
on study treatment.
Dose limiting toxicities
Only one patient experienced a DLT which was grade 3
cardiac chest pain requiring permanent discontinuation of
protocol treatment during cycle 1. No dose de-escalation
step for selumetinib was required. Toxicity associated with
the selumetinib dose of 75 mg bd was manageable.
Toxicity
General infection, raised gamma-glutamyl transpeptidase
(GGT) and low neutrophil count were the most common
grade 3 and 4 adverse events. Grade 3 or 4 toxicities con-
sidered to be related to the administration of selumetinib
occurred in 25 % of patients (Table 2). Three patients
(25 %) developed grade 3 or 4 infections considered to be
related to selumetinib: 2 patients had a skin infection and
1 patient had a bronchial infection. Relatedness to selume-
tinib is given in Additional file 2: Table S1.
Cause of death and PFS
At the time of the final analysis, 7 patients (59 %) had died
and 5 patients (41 %) were alive. The 7 patients who died
and 2 of the patients alive had progressed. Six patients
died due to disease and 1 due to metabolic liver disease
(primary cause) and pulmonary embolism (secondary
cause). None of the deaths were considered to be related
to protocol treatment. The PFS rate at 6 months was 67 %
and at 12 months was 33 % and the median PFS was
6.4 months (IQR 5.2 to 13.7)
.
Objective response
Eight patients were evaluable for objective tumour re-
sponse using RECIST v1.1 (Additional file 3: Table S4).
Median time from documented best objective response
until progression or death is 5.9 months. The patient
who had complete response has no documented pro-
gression or death. The patient who had partial response
had documented progression at 5.9 months. A total out
of 6 patients who had stable disease had a documented
Table 1 Baseline characteristics
Variables Number of patients (%)
Age (years)
Median (IQR) 65 (61 to 68)
Sex
Female 9 (69 %)
Male 4 (31 %)
Primary site
Gall bladder 3 (23 %)
Bile duct 9 (69 %)
Ampulla 1 (8 %)
ECOG PS
0 9 (69 %)
1 4 (31 %)
T-stage
T1 1 (8 %)
T2 0 (0 %)
T3 8 (62 %)
T4 1 (8 %)
TX 3 (23 %)
N-stage
N0 2 (15 %)
N1 5 (38 %)
N2 1 (8 %)
NX 5 (38 %)
M-stage
M0 1 (8 %)
M1a 10 (77 %)
MX 2 (15 %)
Tumour differentiation
Well/Moderately differentiated 6 (46 %)
Poorly differentiated 6 (46 %)
Not specified 1 (8 %)
Previous treatment
None 5 (38 %)
Chemotherapy 0 (0 %)
Surgery 8 (62 %)
Radiotherapy 0 (0 %)
Other 0 (0 %)
2+ types 0 (0 %)
Biliary Stent Insertions 7 (54 %)
aSites of metastasis: 8 patients had liver metastases, 3 had peritoneum, 2 had
lung. Two patients had other metastasis: one had small bowel and the other
had coeliac lymph node positive gastric lymph node
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PFS event (4 had had a documented progression and
death; 1 had documented death only). For patients who
had best objective response SD, the median time from
documented best objective response until progression or
death is 3.1 months.
PK analysis
Eleven patients were evaluable for the PK analysis
(Table 3). Data from one patient was excluded from the
analysis because of extensive missing data. Missing con-
centrations for selumetinib and N-desmethyl selumetinib
(6 values, Additional file 4: Table S3) were imputed
using predicted values from the concentration at the
previous PK time point using linear regression. The
plasma concentration of selumetinib (S) increased in the
presence of CisGem (S + CisGem) compared to when
selumetinib was given alone. In the presence of CisGem,
the ratios of the geometric means of S + CisGem com-
pared to S of AUC (0-t) and AUC (0-∞) of selumetinib
increased by 12 % (ratio S + CisGem:S 1.12 (90 % CI: 0.95
to 1.30)) and 11 % (ratio S + CisGem:S 1.11 (90 % CI: 0.95
to 1.30)), respectively. In the presence of CisGem, the geo-
metric mean of Cmax for selumetinib increased by 30 %
(ratio S + CisGem:S 1.30 (90 % CI: 0.91 to 1.85)). There
was no evidence that Tmax changed in the presence of
CisGem because the median of the paired differences of
Tmax for selumetinib plus CisGem and selumetinib alone
was 0 (90 % CI: -1.09 to 0 .57). The geometric means of
AUC(0-t), AUC (0-∞) and Cmax for the N-desmethyl
metabolite of selumetinib all decreased by 40 % in the pres-
ence of CisGem. Tmax for N-desmethyl selumetinib did
not change in the presence of CisGem (median of paired
differences 0 (90 % CI: -1.13 to 0 .50)).
Discussion
Although significant advances have been made in the man-
agement of patients with ABC, the prognosis remains poor.
The molecular landscape of biliary tract cancers has been
described although clear molecular targets for therapy
remain elusive [11–16]. Clinical trials using anti-epidermal
growth factor antibody in combination with oxaliplatin and
Table 2 Adverse events (worst grade during the trial)
Adverse events (CTCAE v4.03)
a,b
Worst grade
Grades 1 & 2 Grades 3 & 4 Any Grade
N(%) N(%) N(%)
Haemotological
Neutropenia 6 (50 %) 1 (8 %) 7 (58 %)
Platelets 5 (42 %) 3 (25 %) 8 (67 %)
Hb 8 (67 %) 4 (33 %) 12 (100 %)
Neutrophils 5 (42 %) 5 (42 %) 10 (83 %)
Liver function
ALT 6 (50 %) 4 (33 %) 10 (83 %)
AST 11 (92 %) 1 (8 %) 12 (100 %)
Bilirubin 3 (25 %) 1 (8 %) 4 (33 %)
ALP 9 (75 %) 3 (25 %) 12 (100 %)
GGT 6 (50 %) 6 (50 %) 12 (100 %)
Non-haematological
Hypertension 0 (0 %) 1 (8 %) 1 (8 %)
Lethargy 2 (17 %) 0 (0 %) 2 (17 %)
Fatigue 8 (67 %) 2 (17 %) 10 (83 %)
Rash 6 (50 %) 0 (0 %) 6 (50 %)
Anorexia 9 (75 %) 0 (0 %) 9 (75 %)
Nausea 9 (75 %) 0 (0 %) 9 (75 %)
Vomiting 9 (75 %) 0 (0 %) 9 (75 %)
Constipation 9 (75 %) 1 (8 %) 10 (83 %)
Diarrhoea 5 (42 %) 1 (8 %) 6 (50 %)
Oedema 11 (92 %) 0 (0 %) 11 (92 %)
Allergy reaction 1 (8 %) 0 (0 %) 1 (8 %)
Tinnitus 1 (8 %) 0 (0 %) 1 (8 %)
Dyspnoea 3 (25 %) 1 (8 %) 4 (33 %)
Blurred vision 4 (33 %) 0 (0 %) 4 (33 %)
Other
Haemorrhage 2 (17 %) 1 (8 %) 3 (25 %)
Bacteraemia 1 (8 %) 0 (0 %) 1 (8 %)
Fever 7 (58 %) 0 (0 %) 7 (58 %)
Mucositis/oral thrush 8 (67 %) 0 (0 %) 8 (67 %)
Other mucositis 1 (8 %) 0 (0 %) 1 (8 %)
Paronychia 1 (8 %) 1 (8 %) 2 (17 %)
General infection 1 (8 %) 7 (58 %) 8 (67 %)
Biliary sepsis 1 (8 %) 2 (17 %) 3 (25 %)
Sensory neuropathy 5 (42 %) 0 (0 %) 5 (42 %)
Thromboembolic event 0 (0 %) 2 (17 %) 2 (17 %)
Chest pain—cardiac 1 (8 %) 1 (8 %) c 2 (17 %)
Non-specific pain 9 (75 %) 1 (8 %) 10 (83 %)
Pancreatitis 1 (8 %) 0 (0 %) 1 (8 %)
Alopecia 3 (25 %) 0 (0 %) 3 (25 %)
Heart failure 0 (0 %) 1 (8 %) 1 (8 %)
Table 2 Adverse events (worst grade during the trial)
(Continued)
Nasal discharge/congestion 4 (33 %) 0 (0 %) 4 (33 %)
Dyspepsia/Dysphagia 5 (42 %) 0 (0 %) 5 (42 %)
Retinal vascular disorder 1 (8 %) 0 (0 %) 1 (8 %)
Depressive symptoms 1 (8 %) 1 (8 %) 2 (17 %)
Palmar-plantar erythema 1 (8 %) 0 (0 %) 1 (8 %)
Other adverse events 11 (92 %) 0 (0 %) 11 (92 %)
aOne patient can appear in more than one row
bPercentages are based on a total of 12 patients. One patient did not
start treatment
cThis adverse event was considered a DLT (Grade 3)
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gemcitabine in a randomised phase II study failed to dem-
onstrate benefit for the experimental arm [17]. Another
randomised phase II study of gemcitabine with or without
sorafenib also failed to demonstrate benefit for the experi-
mental arm [18]. The randomised phase II ABC-03 study
which allocated patients to CisGem and placebo or CisGem
plus cediranib showed no difference in PFS [19].
The role for targeted agents in biliary tract cancer is
uncertain and benefit from these drugs is likely to re-
quire identification of molecular profiles in this patient
group that predict outcome. Although preclinical data in
breast and non-small cell lung cancers [20] suggest bio-
markers predictive of response, there are significant dif-
ferences between types of cancer and also heterogeneity
within individual cancers themselves. Next Generation
Sequencing data of biliary tract cancers [12, 21] suggest
a disparate molecular genotype, with some studies show-
ing a high frequency of BAP1, ARID1A and PBRM1 mu-
tations and others TP53, KRAS and SMAD4. Further
data suggest the single largest subgroup are those with
amplified HER2 expression [16]. To this end, there is
ongoing translational analysis of the ABC-04 material.
In ABC-04 one dose limiting toxicity was observed,
which was cardiac chest pain in a patient not known to
have coronary artery disease. There was a clear temporal
relationship between selumetinib administration and chest
pain and this has not been seen in patients treated with
CisGem chemotherapy alone, including the ABC-02 study
[1]. In general, the combination of CisGem+ selumetinib
was delivered with manageable toxicity at a dose of 75 mg
bd. This was the recommended dose determined by similar
studies of selumetinib-chemotherapy combinations [6, 7]
and, as expected, no dose de-escalation was required
in our study. The impact of CisGem on selumetinib
and N-desmethyl selumetinib AUC is interesting in
view of the increased potency of the metabolite and
would suggest a considering a higher dose level to reach
MTD in future studies. As such however, the dose level
described here represents the current dose for use in com-
bination with CisGem for future investigation.
A role for selumetinib has been defined in uveal melan-
oma [22], melanoma [7] and non-small cell lung cancer
[6]. MEK inhibitors have also shown promise in pancreatic
cancer. Analysis of the mechanisms of MEK resistance
have demonstrated up-regulation of regulators in parallel
pathways suggesting combinations of pathway inhibition
may be required to optimally reduce the growth signal
[23–25]. We conclude that selumetinib can be given with
CisGem in advanced biliary tract cancer at the dose of
75 mg bd with manageable toxicity. Its role as an effective
therapy will be determined by randomised phase II and III
studies in the context of molecular profiling. We would
propose further investigation of this combination.
Conclusion
The recommended dose of selumetinib when combined
with CisGem was 75 mg bd. Translational studies are un-
derway to identify biomarkers that may predict outcome.
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transaminase; AUC: Area under the curve; bd: Twice daily; CisGem: ABC-02
Table 3 Pharmacokinetic parameters of selumetinib, by treatment combinations (75 mg bd)
Compound PK Parametersa Nb Sel + CisGem Selumetinib alone Sel vs Sel + CisGem Effect (90 % CI)e
Selumetinib AUC(0-t) (ng-hr/mL) 11 5304.37 4757.16 1.12 (0.95 to 1.30)
AUC(0-∞) (ng-hr/mL)c 11 6286.25 5653.31 1.11 (0.95 to 1.30)
Cmax (ng/mL) 11 1725.64 1331.33 1.30 (0.91 to 1.85)
Tmax (hours)d 11 1.50 1.55 0 (−1.09 to 0 .57)
N-desmethyl selumetinib AUC(0-t) (ng-hr/mL) 11 216.83 347.26 0.62 (0.43 to 0.91)
AUC(0-∞) (ng-hr/mL)c 11 277.55 452.88 0.61 (0.42 to 0.89)
Cmax (ng/mL) 11 48.41 77.16 0.63 (0.43 to 0.91)
Tmax (hours)d 11 1.62 2.00 0 (−1.13 to 0 .50)
aAnalysis used the actual time points when PK samples were collected. PK time point 0 corresponded to the time selumetinib was administered. Missing times of
selumetinib dose administration were imputed from the non-missing time points. Missing concentrations for selumetinib and N-desmethyl selumetinib were
estimated using linear interpolation
bOf 12 patients, 11 were evaluable for PK analysis. Patients evaluable for PK analysis included the patients for whom a PK parameter could be imputed
cLog linear models were used to extrapolate AUC (0-∞) using the last three measurements
dTmax is expressed in terms of medians
eRatio of geometric means between selumetinib and selumetinib + CisGem for AUC(0-t), AUC(0-∞) and Cmax. Rank-based difference in paired medians for Tmax
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cisplatin gemcitabine regimen; CLRN: Comprehensive Local Research
Network; CL/F: Apparent oral clearance; Cmax: Maximum concentraion;
CT: Computer tomography; CTCAE: Common terminology criteria for adverse
events; DLT: Dose limiting toxicity; ERK: Extracellular-signal-regulated kinase;
GGT: Gamma-glutamyl transpeptidase; GFR: Glomerular filtration rate;
IQR: Interquadrantic ratio; IV: Intravenously; MEK1/2: Mitogen-activated
protein kinase kinase 1; mg/m2: Milligrams/metre squared; MRI: Magnetic
resonance imaging; NHS: National Health Service; NIHR: National Institute for
Health Research; od: Once daily; ORR: Objective tumour response rate;
OS: Overall survival; pERK: Phosporylated ERK; PK: Pharmacokinetics;
PFS: Progression free survival; RAF: RAF proto-oncogene; RAS: Rous Sarcoma
virus proto-oncogene; RECIST: Response Evaluation Criteria in Solid Tumours;
S: Selumetinib; S + CisGem: Selumetinib and CisGem; tmax: Time to Cmax;
ULN: Upper limit of normal; WHO: World health organisation.
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